Coronary Artery Disease - Pipeline Insight, 2024

This “Coronary Artery Disease - Pipeline Insight, 2024,” report provides comprehensive insights about 30+ companies and 25+ pipeline drugs in Coronary Artery Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Coronary Artery Disease Understanding

Coronary Artery Disease: Overview

Coronary artery disease is a common heart condition. Coronary artery disease may also be called coronary heart disease. The major blood vessels that supply the heart (coronary arteries) struggle to send enough blood, oxygen and nutrients to the heart muscle. Cholesterol deposits (plaques) in the heart arteries and inflammation are usually the cause of coronary artery disease.

Signs and symptoms of coronary artery disease occur when the heart doesn't get enough oxygen-rich blood. If you have coronary artery disease, reduced blood flow to the heart can cause chest pain (angina) and shortness of breath. A complete blockage of blood flow can cause a heart attack. Coronary artery disease often develops over decades. Symptoms may go unnoticed until a significant blockage causes problems or a heart attack occurs.

Coronary Artery Disease - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Coronary Artery Disease pipeline landscape is provided which includes the disease overview and Coronary Artery Disease treatment guidelines. The assessment part of the report embraces, in depth Coronary Artery Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Coronary Artery Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Coronary Artery Disease R&D. The therapies under development are focused on novel approaches to treat/improve Coronary Artery Disease.

Coronary Artery Disease Emerging Drugs Chapters

This segment of the Coronary Artery Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Coronary Artery Disease Emerging Drugs

Flurpiridaz F-18: GE HealthcareFlurpiridaz F-18, a fluorine 18-labeled agent was developed by Lantheus Medical Imaging for the diagnosis of coronary artery disease (CAD), the most common form of heart disease. Flurpiridaz F 18 is an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent. GE Healthcare has launched a second Phase III clinical trial for the use of Flurpiridaz 18F Injection in PET myocardial perfusion imaging (MPI) to detect CAD. Currently, it is in Phase III stage of clinical trial evaluation to treat Coronary Artery Disease.

Evolocumab: AmgenEvolocumab injection is used to reduce the risk of a stroke or heart attack or the need for coronary artery bypass (CABG) surgery in people with cardiovascular disease. Evolocumab injection is also used along with diet alone or in combination with other cholesterol-lowering medications such as HMG-CoA reductase inhibitors (statins) or ezetimbe (Zetia) to decrease the amount of low-density lipoprotein (LDL) cholesterol ('bad cholesterol') in the blood, including people who have familial heterozygous hypercholesterolemia. It is also used along with diet changes and other treatments to reduce the amount low-density lipoprotein (LDL) cholesterol in the blood in people that have homozygous familial hypercholesterolemia. It is in a class of medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor monoclonal antibody. It works by blocking the production of LDL cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body. Currently, it is in Phase III stage of clinical trial evaluation to treat Coronary Artery Disease.

Revacept: advanceCorRevacept seals the lesion in a blood vessel like a plaster. It acts locally at the ruptured plaque instead of involving the complete organism, as is the case for all established drugs. Revacept has proven to be very effective in laboratory tests with platelets and in animal experiments. In a Phase I clinical trial with volunteers, it was shown to be very well tolerated at all dosages. It induced a specific and dose-dependent inhibition of aggregation (clumping of platelets) in the blood of the volunteers without any relevant side effects. In particular, general haemostasis was not affected: The bleeding time was not prolonged by Revacept and there were no bleeding complications and no reduction in platelet count (thrombopenia). Currently, it is in Phase II stage of clinical trial evaluation to treat Coronary Artery Disease.

Coronary Artery Disease: Therapeutic Assessment

This segment of the report provides insights about the different Coronary Artery Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Coronary Artery Disease

There are approx. 30+ key companies which are developing the therapies for Coronary Artery Disease. The companies which have their Coronary Artery Disease drug candidates in the most advanced stage, i.e. phase III include, Amgen.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Coronary Artery Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Coronary Artery Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Coronary Artery Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Coronary Artery Disease drugs.

Coronary Artery Disease Report Insights

• Coronary Artery Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Coronary Artery Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Coronary Artery Disease drugs?
• How many Coronary Artery Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Coronary Artery Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Coronary Artery Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Coronary Artery Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis Pharmaceuticals
• Amgen
• Imbria Pharmaceuticals, Inc.
• AstraZeneca
• Jiangsu Vcare Pharmatech
• GE Healthcare

Key Products

• Flurpiridaz F18
• Evolocumab
• Inclisiran
• Ninerafaxstat
• MEDI6570
• Vicagrel

This product will be delivered within 1-3 business days.